Anticoagulant Use During Extracorporeal Membrane Oxygenation Using Heparin and Direct Thrombin Inhibitors in COVID-19 and ARDS Patients.
暂无分享,去创建一个
A. Sestokas | M. Firstenberg | A. Stammers | L. Mongero | Eric A. Tesdahl | K. Patel | M. Mosca | Shannon Barletti | J. Jacobs
[1] Paramita Paul,et al. Current challenges in different approaches to control COVID-19: a comprehensive review , 2022, Bulletin of the National Research Centre.
[2] Diego Velasco-Rodríguez,et al. A journey through anticoagulant therapies in the treatment of left ventricular thrombus in post-COVID-19 heparin-induced thrombocytopenia: a case report , 2022, Hematology.
[3] A. Scandroglio,et al. Anticoagulation Strategies in Critically Ill Patients With SARS-CoV-2 Infection: The Role of Direct Thrombin Inhibitors , 2022, Journal of Cardiothoracic and Vascular Anesthesia.
[4] J. Veličković,et al. D-dimer, CRP, PCT, and IL-6 Levels at Admission to ICU Can Predict In-Hospital Mortality in Patients with COVID-19 Pneumonia , 2022, Oxidative medicine and cellular longevity.
[5] A. Sestokas,et al. Multi-institutional Analysis of 505 COVID-19 Patients Supported with ECMO: Predictors of Survival , 2022, Annals of Thoracic Surgery.
[6] P. Wells,et al. Thromboprophylaxis in Patients With COVID-19 , 2022, Chest.
[7] K. Lewandowska,et al. Thromboprophylaxis in patients with Covid-19 , 2022, Acta Angiologica.
[8] E. Fan,et al. 2021 ELSO Adult and Pediatric Anticoagulation Guidelines. , 2022, ASAIO journal.
[9] T. Welte,et al. Intracranial Hemorrhages on Extracorporeal Membrane Oxygenation: Differences Between COVID-19 and Other Viral Acute Respiratory Distress Syndrome , 2022, Critical care medicine.
[10] D. Brodie,et al. Bleeding and thrombotic events in adults supported with venovenous extracorporeal membrane oxygenation: an ELSO registry analysis , 2021, Intensive Care Medicine.
[11] R. Kapoor,et al. Efficacy of Bivalirudin for Therapeutic Anticoagulation in COVID-19 Patients Requiring ECMO Support , 2021, Journal of Cardiothoracic and Vascular Anesthesia.
[12] L. Sattler,et al. Argatroban for Anticoagulation in Patients Requiring Venovenous Extracorporeal Membrane Oxygenation in Coronavirus Disease 2019 , 2021, Critical care explorations.
[13] H. ten Cate. Surviving Covid-19 with Heparin? , 2021, The New England journal of medicine.
[14] Christopher M. Horvat,et al. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19 , 2021, The New England journal of medicine.
[15] L. Camporota,et al. A Comparison of Thrombosis and Hemorrhage Rates in Patients With Severe Respiratory Failure Due to Coronavirus Disease 2019 and Influenza Requiring Extracorporeal Membrane Oxygenation , 2021, Critical care medicine.
[16] B. Zieger,et al. Hypercoagulopathy, acquired coagulation disorders and anticoagulation before, during and after extracorporeal membrane oxygenation in COVID-19: a case series , 2021, Perfusion.
[17] R. Rivosecchi,et al. Comparison of Anticoagulation Strategies in Patients Requiring Venovenous Extracorporeal Membrane Oxygenation: Heparin Versus Bivalirudin* , 2021, Critical care medicine.
[18] D. Brodie,et al. Extracorporeal Membrane Oxygenation for COVID-19: Updated 2021 Guidelines from the Extracorporeal Life Support Organization , 2021, ASAIO journal.
[19] T. Rice,et al. Bleeding, Thromboembolism, and Clinical Outcomes in Venovenous Extracorporeal Membrane Oxygenation , 2020, Critical care explorations.
[20] Hongtao Zhang,et al. Structural Features and PF4 Functions that Occur in Heparin-Induced Thrombocytopenia (HIT) Complicated by COVID-19 , 2020, Antibodies.
[21] Lin Sun,et al. Anticoagulation Management in Severe Coronavirus Disease 2019 Patients on Extracorporeal Membrane Oxygenation , 2020, Journal of Cardiothoracic and Vascular Anesthesia.
[22] Kholoud F. Aliter,et al. Thrombin Inhibition by Argatroban: Potential Therapeutic Benefits in COVID-19 , 2020, Cardiovascular Drugs and Therapy.
[23] A. Fauci,et al. Emerging Pandemic Diseases: How We Got to COVID-19 , 2020, Cell.
[24] Salim E. Olia,et al. A Case Series of Devastating Intracranial Hemorrhage During Venovenous Extracorporeal Membrane Oxygenation for COVID-19 , 2020, Journal of Cardiothoracic and Vascular Anesthesia.
[25] T. Seelhammer,et al. Bivalirudin for Maintenance Anticoagulation During Venovenous Extracorporeal Membrane Oxygenation for COVID-19 , 2020, Journal of Cardiothoracic and Vascular Anesthesia.
[26] J. Connors,et al. Thromboinflammation and the hypercoagulability of COVID‐19 , 2020, Journal of Thrombosis and Haemostasis.
[27] N. Smischney,et al. Anticoagulation with direct thrombin inhibitors during extracorporeal membrane oxygenation , 2019, World journal of critical care medicine.
[28] G. Schears,et al. Adult extracorporeal membrane oxygenation: an international survey of transfusion and anticoagulation techniques , 2017, Vox sanguinis.
[29] E. Conway,et al. Cross Talk Pathways Between Coagulation and Inflammation. , 2016, Circulation research.
[30] Isaac Subirana,et al. Building Bivariate Tables: The compareGroups Package for R , 2014 .
[31] M. Ranucci. Bivalirudin and post-cardiotomy ECMO: a word of caution , 2012, Critical Care.
[32] M. Ranucci,et al. Bivalirudin-based versus conventional heparin anticoagulation for postcardiotomy extracorporeal membrane oxygenation , 2011, Critical care.
[33] J. Ansell,et al. Direct thrombin inhibitors. , 2011, British journal of clinical pharmacology.
[34] P. Aylward,et al. Bivalirudin pharmacokinetics and pharmacodynamics: Effect of renal function, dose, and gender , 2002, Clinical pharmacology and therapeutics.
[35] Gail,et al. ELSO Adult and Pediatric Anticoagulation Guidelines , 2022 .
[36] R. Rivosecchi,et al. 841: Comparison of 4-Factor Prothrombin Complex Concentrate Dosing Strategies for Warfarin Reversal , 2020 .
[37] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .